콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

Y0001387

Candesartan cilexetil for peak identification

European Pharmacopoeia (EP) Reference Standard

동의어(들):

Candesartan cilexetil, 2-ethoxy-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-Benzimidazole-7-carboxylic acid 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, TCV 116, TCY 116

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C33H34N6O6
CAS Number:
Molecular Weight:
610.66
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

candesartan

제조업체/상표

EDQM

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc4ccc(cc4)-c5ccccc5-c6nnn[nH]6

InChI

1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38)

InChI key

GHOSNRCGJFBJIB-UHFFFAOYSA-N

유전자 정보

human ... AGTR1(185)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Candesartan cilexetil for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

생화학적/생리학적 작용

Candesartan cilexetil is a non-peptide angiotensin (AT2) receptor antagonist.
Candesartan cilexetil is the prodrug form of the potent angiotensin II receptor antagonist, candesartan. The prodrug is cleaved by esterases within the intestine to liberate the active molecule.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

관련 제품

제품 번호
설명
가격

픽토그램

Health hazard

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Repr. 1B - STOT RE 2 Oral

표적 기관

Kidney,Blood

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 문서 section.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Shinji Yasuno et al.
Expert review of cardiovascular therapy, 10(5), 577-583 (2012-06-02)
Hypertension is one of the most prevalent disorders and the largest contributor to global mortality. The aim of antihypertensive treatment is to reduce the risk of cardiovascular morbidity and mortality by lowering increased blood pressure (BP) to target levels. Despite
Peter A Meredith
Current medical research and opinion, 23(7), 1693-1705 (2007-06-26)
Therapeutic interventions that block the renin-angiotensin-aldosterone system (RAAS) have an important role in slowing the progression of cardiovascular risk actors to established cardiovascular diseases. In recent years, angiotensin receptor blockers (ARBs) have emerged as effective and well-tolerated alternatives to an
Naoki Ichikawa et al.
Neurological research, 37(2), 147-152 (2014-08-05)
The purpose of this study was to examine whether oral administration of an angiotensin II type 1 receptor blocker (ARB) inhibited in-stent neointimal hyperplasia in carotid arteries of hypercholesterolemic rabbits. Eleven male New Zealand white rabbits were subjected to endothelial
Greg L Plosker et al.
PharmacoEconomics, 24(12), 1249-1272 (2006-11-30)
The addition of candesartan cilexetil (Atacand, Amias, Blopress, Kenzen, Ratacand) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany and the UK, according to a detailed economic analysis
G Mancia et al.
Journal of human hypertension, 14 Suppl 2, S3-10 (2000-11-22)
The prevention and treatment of hypertension both from the viewpoint of individual patient care and in terms of population health presents a considerable challenge to the medical profession. To assist in meeting this challenge, various bodies have produced guidelines for

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.